Plain-English translation of NCT06135909 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This is a large study across multiple hospitals in China that follows people like you who have pulmonary hypertension โ a condition where blood pressure in the lungs gets dangerously high. The study tracks how you respond to targeted drugs (including prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists, and prostacyclin receptor agonists) to understand what works best in real-world medical practice.
Doctors want to understand how these medications actually work for patients in everyday clinical care and identify which people improve the most, get worse, or face complications. By collecting this real-world information from many patients, researchers can better understand how to manage this serious condition.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will visit the hospital every 6 months for the next 3 years to have your health checked. During these visits, doctors will measure your exercise tolerance, check your heart function with ultrasound or blood tests, and ask about any side effects or changes in your symptoms. The study collects information about your disease progress, hospitalizations, medication use, and how well the treatment is working for you.
AI-generated summary from trial data ยท Jun 8, 2026 ยท Not medical advice
China
Chinese Pulmonary Vascular Disease Research Group
Enrollment target
~5,000 participants
Started
January 2020
Primary completion
December 2027
Age range
18 Years โ 85 Years
Last updated on clinicaltrials.gov in January 2024.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Zhihong Liu, M.D., Ph.D
Chinese Academy of Medical Sciences, Fuwai Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.